Holen Sie sich die Stockscreener-App
1.65
3.44%
0.05
Handel nachbörslich:
1.62
-0.03
-1.82%
Schlusskurs vom Vortag:
$1.60
Offen:
$1.59
24-Stunden-Volumen:
467.70K
Relative Volume:
0.58
Marktkapitalisierung:
$175.90M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-4.8529
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
+6.77%
1M Leistung:
+14.14%
6M Leistung:
-36.35%
1J Leistung:
-57.24%
1-Tages-Spanne:
$1.5301
$1.67
1-Wochen-Bereich:
$1.515
$1.71
52-Wochen-Spanne:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.65 | 170.57M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
133.26 | 228.66B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
96.24 | 140.69B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.88 | 139.51B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.53 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.35 | 42.83B | 5.69B | 1.41B | 577.90M | 6.9828 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
What dividend safety rating applies to MaxCyte Inc. (MYE0) stockJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Why MaxCyte Inc. stock remains a top recommendation2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
Is MaxCyte Inc. trending in predictive chart modelsMarket Performance Report & Verified Stock Trade Ideas - newser.com
Is MaxCyte Inc. stock a buy in volatile marketsJuly 2025 Levels & Low Risk Entry Point Guides - newser.com
Will MaxCyte Inc. stock recover faster than peers2025 Earnings Impact & Daily Volume Surge Trade Alerts - newser.com
Predicting MaxCyte Inc. trend using moving averagesWeekly Volume Report & Safe Entry Point Alerts - newser.com
MaxCyte cuts 15% of global workforce, boosts core revenue guidance - MSN
MaxCyte announces 34% workforce reduction to cut costs - MSN
Will MaxCyte Inc. (MYE0) stock deliver stable dividendsRate Cut & Low Risk Growth Stock Ideas - newser.com
MaxCyte Inc. recovery potential after sell offPortfolio Profit Report & Daily Chart Pattern Signal Reports - newser.com
Real time social sentiment graph for MaxCyte Inc.Quarterly Performance Summary & Daily Chart Pattern Signals - newser.com
Farther Finance Advisors LLC Raises Holdings in MaxCyte, Inc. $MXCT - Defense World
Is this a good reentry point in MaxCyte Inc.July 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Will MaxCyte Inc. (MYE0) stock see valuation expansion2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Applying big data sentiment scoring on MaxCyte Inc.July 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Market reaction to MaxCyte Inc.’s recent news2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Applying sector rotation models to MaxCyte Inc.July 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
How to use a screener to detect MaxCyte Inc. breakoutsJuly 2025 Update & High Accuracy Trade Alerts - newser.com
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | Oklahoma City NewsThe Oklahoman - FinancialContent
MaxCyte, Inc. Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - MarketScreener
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Can MaxCyte Inc. stock deliver sustainable ROEQuarterly Market Summary & Reliable Breakout Forecasts - newser.com
Intraday pattern recognizer results for MaxCyte Inc.Short Setup & Verified Swing Trading Watchlists - newser.com
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
What analysts say about MaxCyte Inc stockTrade Execution Strategies & The Best Picks Hiding in Plain Sight - earlytimes.in
Tick level data insight on MaxCyte Inc. volatilityJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Automated trading signals detected on MaxCyte Inc.Weekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
MaxCyte Inc Stock Analysis and ForecastSupport Zone Identification & Master Timing Market Moves - earlytimes.in
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.22%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):